Ocugen is trading at $0.82, up 10.29%, after reporting third-quarter results on November 4. - Revenue of $1.95 million exceeded estimates; net loss was $0.01 per share. - The company highlighted $84.6 million in cash and an expected runway into 2028. - OCU400 Phase 3 topline data are expected in Q1 2027. A broader biotech rally may have added support, but earnings and the pipeline update are the clearest company-specific catalysts.